Tuesday, 16 Oct 2018

You are here

ESRD Death Declines in Vasculitis Patients

 

In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.

During the years 2010-2014, the mortality rate from ESRD among patients with GPA fell to 15.3 per 100 patient-years from 19 per 100 in 1995-1999, for an adjusted mortality hazard ratio for the later cohort of 0.77 (95% CI 0.66-0.90, P=0.005), according to Zachary S. Wallace, MD, of Harvard Medical School in Boston, and colleagues.

"These findings are encouraging and likely reflect improved management of both GPA and ESRD," the researchers wrote in Arthritis Care & Research.

GPA is a type of vasculitis characterized by inflammation of the small and medium vessels, with renal involvement occurring in 70%. Approximately one-quarter of those with kidney manifestations develop ESRD, which is associated with early death from cardiovascular disease and infection.

Because data on the incidence and mortality associated with ESRD in GPA are currently lacking, Wallace's group examined outcomes in a national ESRD registry for the years 1995 to 2014.

The United States Renal Data System includes more than 90% of patients on dialysis or who have received a kidney transplant, with nephrologists being required to submit a report detailing the cause of ESRD as well as demographics and comorbidities for each patient initiating treatment.

Patients were divided according to year of entry into the database: 1995-1999, 2000-2004, 2005-2009, and 2010-2014. The earliest cohort was considered the reference group.

Their mean age at ESRD diagnosis was around 60 across the time frames, and slightly under 60% were men. Some comorbidities varied over time, with diabetes increasing from 7.3% in the 1995-1999 group to 20.1% in the 2010-2014 group, and hypertension rising from 52.5% to 76.8%.

Those trends were "concerning," according to the researchers. "While these trends likely reflect those in the general population, these findings highlight the importance of assessing and addressing modifiable risk factors in GPA patients to minimize the risk of cardiovascular events," they stated.

During the entire study period, 5,929 patients developed GPA-associated ESRD. Overall incidence rates per million U.S. population for the 5-year subgroups initially increased from 0.81 (95% CI 0.70-0.92) in 1995-1999 to 0.94 (95% CI 0.83-1.05) in 2000-2004, and then to 1.15 (95% CI 1.03-1.27) in 2005-2009, then stabilizing in the 2010-2014 group, at 1.12 per million (95% CI 1-1.24).

This recent stabilization "could reflect advances in the management of patients with GPA in recent years, as it suggests that fewer GPA patients are progressing to ESRD, given stable GPA incidence itself," the authors noted.

Overall, there were 1,795 deaths from ESRD among GPA patients. The incidence of death per 100 patient-years was 19 (95% CI 17.2-21.1) in 1995-1999, 16.9 (95% CI 15.4-18.7) in 2000-2004, 16.2 (95% CI 14.9-17.7) in 2005-2009, and 15.3 (95% CI 14-16.7) in 2010-2014 (P for trend =0.01).

After adjusting for multiple factors including age, sex, body mass index, comorbidities, region of the country, and smoking, the hazard ratios for mortality compared with 1995-1999 were 0.90 (95% CI 0.77-1.05) for 2000-2004 and 0.82 (95% CI 0.71-0.96) for 2005-2009 (P for trend = 0.005).

The results on mortality were similar after additional adjustment for whether a patient was given a transplant, the researchers noted.

Cardiovascular disease was the most common cause of death (30%) during the overall study period, followed by infection (16%). Among the infectious causes of death, 61% related to sepsis and 29% to pneumonia.

Compared with the 1995-1999 cohort, the age- and sex-adjusted hazard ratios for mortality from cardiovascular disease in the various cohorts were (P<0.001 for trend):

2000-2004: 0.84 (95% CI 0.65-1.08)

2005-2009: 0.57 (95% CI 0.45-0.74)

2010-2014: 0.64 (95% CI 0.50-0.82)

For infectious mortality, the hazard ratios for the groups, respectively, were 0.84 (95% CI 0.59-1.19), 0.79 (95% CI 0.57-1.09), and 0.47 (95% CI 0.32-0.67, P<0.001 for trend).

"Despite these improvements, cardiovascular disease and infection remain common causes of death in GPA-ESRD. Future studies evaluating cardiovascular risk management and the risks and benefits of immunosuppression in ESRD patients are necessary," the authors concluded.

A study limitation was the lack of information in the database on treatment of GPA and comorbidities.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.